A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fed)

• Status: RECRUITING
• Trial end date: 2026-07-05

Summary

This was an open-label, randomized, fed, single-dose, 2-sequence, 2- period crossover study to evaluate the pharmacokinetics and safety between single oral administration of "BR3006" and co-administration of "BR3006A", "BR3006B," and "BR3006C" in healthy adult volunteers.

• Phase: PHASE1

Details

• Lead Sponsor: Boryung Pharmaceutical Co., Ltd
• Treatments: dapagliflozin; Metformin; Pioglitazone